Safety and efficacy of laparoscopic ultrasound-guided radiofrequency ablation for malignant liver tumors

doi:10.3877/cma.j.issn.2095-3232.2025019

Abstract

Abstract:

Objective

To evaluate the safety and efficacy of laparoscopic ultrasound (LUS)-guided radiofrequency ablation (RFA) in the treatment of malignant liver tumors.

Methods

Clinical data of

47 patients with malignant liver tumors who underwent LUS-guided RFA in Beijing Luhe Hospital affiliated

to Capital Medical University from January 2017 to June 2022 were retrospectively analyzed.The informed consents of all patients were obtained and the local ethical committee approval was received.Among them, 33 patients were male and 14 female, aged from 37 to 86 years, with a median age of 64 years.14 patients were diagnosed with hepatocellular carcinoma (HCC) and 33 cases of colorectal cancer liver metastasis (CRLM).The tumor diameter was ranged from 0.5 to 3.5 cm, with a median diameter of 1.6 cm.The complete ablation rate and perioperative complications were observed.The survival and tumor recurrence were recorded during follow-up.Survival analysis was performed by Kaplan-Meier method.

Results

All procedures were successfully completed without conversion to open surgery.72 lesions from 47 patients were treated with RFA.The median number of liver tumors treated by RFA was 1.5 (1.0-5.0).The complete ablation rate reached 97%(70/72).Transaminase levels were increased to different degrees at postoperative 1 d, and then significantly decreased at postoperative 3 d.One case developed postoperative liver abscess, which was cured by puncture and drainage.No severe complications and death occurred during perioperative period.The length of postoperative hospital stay was 4.6 (1.0-12.0) d.The postoperative 1- and 3-year overall survival rates were 95.8% and 90.3%, and the 1- and 3-year recurrence-free survival rates were 82.3% and 67.7%,respectively.

Conclusions

LUS-guided RFA is a simple, safe and efficacious treatment for malignant liver tumors, which yields a low incidence of postoperative complications and satisfactory therapeutic effect.It can be utilized as an important treatment for patients ineligible for surgical resection.

Key words: Liver neoplasms, Carcinoma, hepatocellular, Colorectal cancer liver metastases(CRLM), Laparoscopic ultrasonography, Radiofrequency ablation

Feng Qiu, Tianchi Yang, Wei Han. Safety and efficacy of laparoscopic ultrasound-guided radiofrequency ablation for malignant liver tumors[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 102-106.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2025019

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2025/V14/I01/102

Figures/Tables 3

References 28

[1]	郑荣寿, 张思维, 孙可欣,等.2016年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志, 2023, 45(3):212-220.
[2]	张雯雯, 王宏光, 史宪杰.腹腔镜超声引导下肝肿瘤射频消融治疗的研究进展[J].解放军医学院学报, 2016, 37(5):514-517, 521.
[3]	中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2024 年版 )[J/OL].中华肝脏外科手术学电子杂志, 2024,13(4):407-449.
[4]	Gillams A, Goldberg N, Ahmed M, et al.Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013[J].Eur Radiol, 2015, 25(12):3438-3454.
[5]	Birsen O, Aliyev S, Aksoy E, et al.A critical analysis of postoperative morbidity and mortality after laparoscopic radiofrequency ablation of liver tumors[J].Ann Surg Oncol, 2014, 21(6):1834-1840.
[6]	双剑博, 吴楠, 严琦敏, 等.超声引导结合腹腔镜对高危部位肝癌的微波消融治疗[J].中华普通外科杂志, 2019, 34(5):449-450.
[7]	张寅, 吴贤, 谢炳銮, 等.膈面肝肿瘤腹腔镜超声引导消融治疗体会[J].上海交通大学学报(医学版), 2023, 43(3):391-396.
[8]	王智, 池嘉昌, 翟博.超声引导下经皮微波消融治疗膈顶部肝癌的疗效观察[J].介入放射学杂志, 2020, 29(3):305-309.
[9]	Santambrogio R, Opocher E, Zuin M, et al.Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class a liver cirrhosis[J].Ann Surg Oncol,2009, 16(12):3289-3298.
[10]	Salama IA, Korayem E, ElAbd O, et al.Laparoscopic ultrasound with radiofrequency ablation of hepatic tumors in cirrhotic patients[J].J Laparoendosc Adv Surg Tech A, 2010, 20(1):39-46.
[11]	Foroutani A, Garland AM, Berber E, et al.Laparoscopic ultrasound vs triphasic computed tomography for detecting liver tumors[J].Arch Surg, 2000, 135(8):933-938.
[12]	Kim PN, Choi D, Rhim H, et al.Planning ultrasound for percutaneous radiofrequency ablation to treat small (≤ 3 cm) hepatocellular carcinomas detected on computed tomography or magnetic resonance imaging: a multicenter prospective study to assess factors affecting ultrasound visibility[J].J Vasc Interv Radiol, 2012, 23(5): 627-634.
[13]	Ko SE, Lee MW, Min JH, et al.Laparoscopic radiofrequency ablation of subcapsular hepatocellular carcinomas: risk factors related to a technical failure[J].Surg Endosc, 2022, 36(1):504-514.
[14]	陈敏山.中国肿瘤整合诊治指南-肝癌(2022精简版)[J].中国肿瘤临床, 2022, 49(17):865-873.
[15]	Benson AB, D'Angelica MI, Abrams I, et al.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).Hepatobiliary cancers.Version 1.2023[EB/OL].(2023-3-10)[2023-6-30].https://www.nccn.org/guidelines.
[16]	Kennedy TJ, Cassera MA, Khajanchee YS, et al.Laparoscopic radiofrequency ablation for the management of colorectal liver metastases:10-year experience[J].J Surg Oncol, 2013, 107(4):324-328.
[17]	Takahashi H, Akyuz M, Aksoy E, et al.Local recurrence after laparoscopic radiofrequency ablation of malignant liver tumors: results of a contemporary series[J].J Surg Oncol, 2017, 115(7):830-834.
[18]	Machi, Oishi AJ, Sumida K, et al.Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management[J].Cancer J, 2006, 12(4): 318-326.
[19]	Hildebrand P, Leibecke T, Kleemann M, et al.Influence of operator experience in radiofrequency ablation of malignant liver tumours on treatment outcome[J].Eur J Surg Oncol, 2006, 32(4):430-434.
[20]	Takahashi H, Berber E.Role of thermal ablation in the management of colorectal liver metastasis[J].Hepatobiliary Surg Nutr, 2020, 9(1):49-58.
[21]	Ruers T, van Coevorden F, Punt CJ, et al.Local treatment of unresectable colorectal liver metastases: results of a randomized phaseⅡ trial[J].J Natl Cancer Inst, 2017, 109(9): djx015.
[22]	Shady W, Petre EN, Gonen M, et al.Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes-a 10-year experience at a single center[J].Radiology, 2016,278(2):601-611.
[23]	Aliyev S, Agcaoglu O, Aksoy E, et al.Efficacy of laparoscopic radiofrequency ablation for the treatment of patients with small solitary colorectal liver metastasis[J].Surgery, 2013, 154(3):556-562.
[24]	Siperstein AE, Berber E, Ballem N, et al.Survival after radiofrequency ablation of colorectal liver metastases:10-year experience[J].Ann Surg, 2007, 246(4):559-565.
[25]	Hof J, Wertenbroek MW, Peeters PM, et al.Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases[J].Br J Surg, 2016, 103(8):1055-1062.
[26]	Karanicolas J, Jarnagin WR, Gonen M, et al.Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases[J].JAMA Surg, 2013, 148(7):597-601.
[27]	Meijerink MR, Puijk RS, van Tilborg AAJM, et al.Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases: a systematic review and meta-analysis[J].Cardiovasc Intervent Radiol,2018, 41(8):1189-1204.
[28]	Puijk RS, Ruarus AH, Vroomen LGPH, et al.Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phaseⅢ single-blind prospective randomized controlled trial[J].BMC Cancer, 2018, 18(1):821.

项目	情况
年龄[岁，M（Min～Max）]	64（37～86）
性别[例（%）]
男	33（70）
女	14（30）
原发病[例（%）]
HCC	14（30）
CRLM	33（70）
手术方式[例（%）]
肝切除+RFA	11（23）
结直肠癌同期手术切除+肝切除+RFA	13（28）
RFA	23（49）
消融个数[枚，M（Min～Max）]	1.5（1.0～5.0）
消融肿瘤直径[cm，M（Min～Max）]	1.6（0.5～3.5）

项目	情况
年龄[岁，M（Min～Max）]	64（37～86）
性别[例（%）]
男	33（70）
女	14（30）
原发病[例（%）]
HCC	14（30）
CRLM	33（70）
手术方式[例（%）]
肝切除+RFA	11（23）
结直肠癌同期手术切除+肝切除+RFA	13（28）
RFA	23（49）
消融个数[枚，M（Min～Max）]	1.5（1.0～5.0）
消融肿瘤直径[cm，M（Min～Max）]	1.6（0.5～3.5）

Please choose a citation manager

Content to export